Emerging Pathways in COPD: Targeting Inflammation for A Tailored Treatment Approach
Explore the emerging pathways in COPD treatment by targeting inflammation for a tailored approach. Learn about the unmet needs in the COPD treatment landscape and the importance of personalized care for patients. Stay updated on the latest developments and expert opinions in COPD management.
Triple Inhaled Therapy Reduces Cardiopulmonary Risk in COPD Patients
Learn about the promising results of triple inhaled therapy with budesonide/glycopyrrolate/formoterol fumarate in reducing the risk of cardiopulmonary events in individuals with COPD. The post-hoc analysis based on the ETHOS phase 3 clinical trial showed a 20% reduction in risk compared to dual therapy, offering hope for improved outcomes and enhanced quality of life for COPD patients.
New Therapies for COPD Set to Revolutionize Treatment Paradigm in 2024
Learn about the potential paradigm shift in COPD treatment with the imminent entry of new therapies such as Dupixent and Ensifentrine, both of which have successfully met their trial endpoints and are projected to revolutionize the treatment paradigm for COPD. GlobalData anticipates Dupixent to achieve total sales of $21.4 billion globally by 2029, while Ensifentrine is forecast to generate sales of $1.1 billion by the same year. With promising results from two phase 3 clinical trials, Dupixent has the potential to address the current gap in the COPD market due to the absence of biologics.